Goldman Sachs trims its staff, cutting what it deems to be the underperformers. This year, VPs stand to be big targets, BI ...

Goldman Sachs plans to trim its staffing by 3% to 5% in an annual performance review process this spring, said a source ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Goldman Sachs Group Inc.'s stock is weighing on the Dow Jones Industrial Average and Citigroup Inc.'s stock is one of the biggest decliners in the S&P 500 in Tuesday's market drop. Goldman Sachs was ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

It does appear that firmer succession planning is underway,” said Stephen Biggar, a banking analyst at Argus Research.

Pharmaceutical giant Moderna Inc. (NASDAQ:MRNA) lost 7.28 percent of its value on Monday to end the day at $36.55 apiece as investors continued to sell off positions following Goldman Sachs ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...